Please use this identifier to cite or link to this item: http://103.65.197.75:8080/jspui/handle/123456789/230
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBehera, Chinmaya-
dc.date.accessioned2024-11-06T09:49:01Z-
dc.date.available2024-11-06T09:49:01Z-
dc.date.issued2021-01-31-
dc.identifier.issn1410 8046 (print) , 2460 9196 (online)-
dc.identifier.urihttp://103.65.197.75:8080/jspui/handle/123456789/230-
dc.description.abstractAlthough there is a plethora of studies which examine the impact of the COVID-19 pandemic on India’s financial sector, we contribute by investigating the effect of the ongoing COVID-19 pandemic on stock returns of Indian pharmaceutical companies. By employing an event study methodology, our results indicate that the average returns of the pharmaceutical sector are positive during the COVID-19 phase although mixed evidence is found at the firm level. This finding is also robust to alternative model specifications.en_US
dc.language.isoenen_US
dc.publisherBulletin of Monetary Economics and Bankingen_US
dc.subjectCOVID-19; Pharmaceutical companies; Risk; Stock return; Event study analysis.en_US
dc.titleTHE COVID-19 PANDEMIC AND INDIAN PHARMACEUTICAL COMPANIES: AN EVENT STUDY ANALYSISen_US
dc.typeArticleen_US
Appears in Collections:Journal Articles

Files in This Item:
File Description SizeFormat 
Chinmaya Behera- The COVID-19 Pandemic and Indian Pharmaceutical Companies.pdf
  Restricted Access
431.02 kBAdobe PDFView/Open Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.